This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
SparkCures ID | 1102 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 42 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Diagnosis of one of the following by treatment regimen:
Regimen A (FT538 monotherapy in r/r AML)
Regimens B or C (FT538 + mAb in r/r MM)
Exclusion Criteria:
Exclusion Criteria Specific to Regimen A (r/r AML)
Exclusion Criteria Specific to Regimens B and C (r/r MM)
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Fate Therapeutics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors